Garlic

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: heart immunity inflammation

Research Overview

Across the studies reviewed here, garlic—particularly standardized preparations such as aged garlic extract (AGE)—has been most studied for cardiovascular outcomes, with the largest emphasis on blood pressure reduction in hypertension. Multiple randomized, double-blind, placebo-controlled trials evaluate AGE as an adjunct to existing antihypertensive therapy in “treated but uncontrolled” hypertension, including dose-response designs over ~12 weeks. Additional controlled studies examine lipid outcomes in moderately hypercholesterolemic men over longer periods (months), and mechanistic/biomarker-focused work in essential hypertension assesses oxidative stress markers (e.g., 8-OHdG, lipid peroxidation), nitric oxide-related measures, and total antioxidant status. A smaller body of evidence in these studies addresses hemostatic effects, including platelet aggregation and platelet adhesion, typically as secondary outcomes within longer supplementation studies.

The strongest evidence in this set supports a clinically meaningful reduction in blood pressure with garlic extracts in hypertensive populations. A meta-analysis of 12 placebo-controlled trials (n≈738 total) reports significant average reductions in systolic blood pressure (~8 mmHg) and diastolic blood pressure (~4 mmHg) versus placebo, with trial sequential analysis and GRADE assessment described as supporting robustness. Individual RCTs in uncontrolled hypertension similarly report systolic reductions on the order of ~7–12 mmHg over 12 weeks, with generally good tolerability and high acceptability. Evidence for lipid lowering is supportive but more modest in magnitude (e.g., ~6–7% total cholesterol reduction and ~4–5% LDL reduction in one crossover study), while biomarker studies suggest potential antioxidant and oxidative-stress–modulating effects in essential hypertension. Platelet-related findings indicate possible antiplatelet/anti-adhesive effects for AGE in vivo, though the evidence presented is limited to subgroup analyses and selective agonist responses.

Key areas needing more research include standardization and comparability across garlic formulations (e.g., AGE vs other extracts; dosing expressed as S-allylcysteine or other actives), clearer dose–response relationships (including why intermediate doses sometimes appear more effective than higher doses), and longer-term clinical outcomes beyond surrogate endpoints (e.g., cardiovascular events, renal outcomes, and durability of blood pressure effects). Larger, well-controlled trials with consistent background antihypertensive regimens, ambulatory blood pressure monitoring, and rigorous adverse-event and interaction surveillance (notably with antiplatelet/anticoagulant therapies given platelet findings) would strengthen clinical guidance. Mechanistic work linking observed changes in oxidative stress, nitric oxide biology, and platelet function to blood pressure and vascular outcomes would also help clarify causal pathways and identify which patient subgroups benefit most.

1. What conditions has Garlic been studied for?

  • Hypertension (high blood pressure): Multiple placebo-controlled trials and a meta-analysis in hypertensive or uncontrolled hypertensive patients; also studied in essential hypertension and in moderately hypercholesterolemic men with blood pressure as a secondary outcome.

  • Hypercholesterolemia / dyslipidemia: A double-blind crossover study in moderately hypercholesterolemic men assessed total cholesterol and LDL changes with aged garlic extract.

  • Oxidative stress and DNA damage in essential hypertension: Studied biomarkers including 8-OHdG (oxidative DNA damage marker), malondialdehyde (lipid peroxidation), nitric oxide (NO), and total antioxidant status.

  • Platelet function / thrombosis-related measures: Platelet aggregation and platelet adhesion to fibrinogen assessed during a long-term aged garlic extract intervention.

  • Hepatopulmonary syndrome (HPS) in cirrhosis: Randomized placebo-controlled study assessed oxygenation and clinical outcomes over 9–18 months.

  • Blood viscosity: Compared Allium sativum extract vs placebo and vs Ginkgo biloba for effects on blood viscosity.

  • Coronary artery calcification / atherosclerosis progression: Small 1-year randomized, placebo-controlled pilot study measured change in coronary calcium score by electron beam tomography.

2. Does it work in treating those conditions? Summarize the evidence.

  • Hypertension: Yes, evidence supports a modest blood-pressure–lowering effect (especially systolic) in hypertensive/uncontrolled hypertensive patients.

    • Meta-analysis of 12 placebo-controlled trials (405 garlic vs 333 placebo) found significant reductions: systolic BP mean difference -8.121 mmHg (95% CI -10.95 to -5.28) and diastolic BP mean difference -4.256 mmHg (95% CI -5.99 to -2.52), both P<0.0001.

    • Adjunct therapy RCT (12 weeks, 960 mg aged garlic extract/day; 2.4 mg S-allylcysteine): In patients with uncontrolled hypertension (SBP ≥140 at baseline), systolic BP averaged 10.2 ± 4.3 mmHg lower vs placebo over 12 weeks (p=0.03); no significant effect in those with baseline SBP <140.

    • Dose-response RCT (12 weeks; 240/480/960 mg aged garlic extract): Significant systolic reduction in the 480 mg group by 11.8 ± 5.4 mmHg vs placebo (P=0.006); the 960 mg group showed a borderline significant reduction at 8 weeks (-7.4 ± 4.1 mmHg, P=0.07). Diastolic BP changes were not significantly different vs placebo.

    • Essential hypertension multi-arm study (24 weeks; 300–1500 mg/day): Reported significant SBP/DBP reductions in a dose- and duration-dependent manner compared with atenolol and placebo; however, details on randomization/blinding and effect sizes are not provided in the study, limiting certainty.

  • Dyslipidemia: Evidence suggests small improvements in cholesterol, but magnitude is modest and based on limited trials.

    • Double-blind crossover study (7.2 g/day aged garlic extract): Maximal reduction in total cholesterol of 6.1% vs placebo period (or 7.0% vs baseline) and LDL reduction of about 4–4.6%. This is a modest effect and may not substitute for standard lipid-lowering therapy.

  • Oxidative stress biomarkers in essential hypertension: Suggestive benefit, but evidence is small and not clearly placebo-controlled.

    • In 20 essential hypertensive patients given garlic pearls 250 mg/day for 2 months, the study reported a moderate BP decline plus reductions in 8-OHdG, NO, and lipid peroxidation (MDA), with increases in antioxidant vitamins and total antioxidant status. Both hypertensive and normotensive groups received garlic, which limits causal inference versus placebo.

  • Platelet function: Evidence supports reduced platelet aggregation/adhesion with aged garlic extract, but clinical outcome impact is unknown.

    • During a long-term intervention (subgroup analysis), 7.2 g/day aged garlic extract reduced epinephrine-induced and to a lesser degree collagen-induced platelet aggregation, did not inhibit ADP-induced aggregation, and reduced platelet adhesion to fibrinogen by ~30% vs placebo.

  • Hepatopulmonary syndrome (HPS): One RCT suggests clinically meaningful benefit, but replication is needed.

    • After 9 months, garlic increased arterial oxygen levels by 24.66% (83.05 vs 66.62 mmHg; P<0.001) vs a smaller increase with placebo (7.37%). Alveolar–arterial gradient decreased by 28.35% with garlic (P<0.001). Reversal of HPS occurred in 66.67% (14/21) on garlic vs 5% (1/20) on placebo; deaths were 2/21 vs 7/20. Sample size is small, and the study does not detail dosing or adverse events.

  • Blood viscosity: Mixed/limited evidence; garlic appears less effective than ginkgo in the cited study.

    • In a comparison study, Ginkgo biloba produced the greatest reduction in blood viscosity compared with placebo and Allium sativum, suggesting garlic’s effect may be smaller in this endpoint.

  • Coronary artery calcification progression: Preliminary evidence only.

    • In a 1-year pilot RCT (19 completers), coronary calcium score increased 7.5 ± 9.4% with aged garlic extract vs 22.2 ± 18.5% with placebo (P=0.046). No significant differences in cholesterol parameters or CRP were seen. Small sample size and pilot design limit confidence.

3. What health benefits does it have?

  • Lowers blood pressure (especially systolic) in hypertensive/uncontrolled hypertensive patients: Meta-analysis shows ~8 mmHg systolic and ~4 mmHg diastolic reductions vs placebo; RCTs show ~10–12 mmHg systolic reductions in uncontrolled hypertension subgroups.

  • Modest lipid improvements: In moderately hypercholesterolemic men, aged garlic extract reduced total cholesterol (~6%) and LDL (~4–4.6%).

  • Potential antiplatelet effects: Reduced epinephrine/collagen-induced platelet aggregation and ~30% reduced platelet adhesion to fibrinogen in a subgroup analysis, suggesting possible cardiovascular risk-factor modification (clinical event reduction not established).

  • Antioxidant/oxidative stress biomarker improvements (in essential hypertension): Reported reductions in oxidative DNA damage marker (8-OHdG), lipid peroxidation (MDA), and NO levels, with increased total antioxidant status and antioxidant vitamins after supplementation (study design limits certainty).

  • Possible benefit in hepatopulmonary syndrome: Improved oxygenation and higher reversal rate vs placebo in a small RCT; if confirmed, could be clinically important for a difficult-to-treat condition.

  • Possible slowing of coronary calcification progression: Pilot RCT suggests reduced progression of coronary calcium score over 1 year vs placebo.

4. Does it have any downsides or side effects?

  • Tolerability generally high in the hypertension RCTs: In the 12-week adjunct trial, aged garlic extract was “generally well tolerated” with high acceptability (92%). In the dose-response trial, tolerability/compliance/acceptability were high (93%), highest with 1–2 capsules/day.

  • Potential bleeding risk is a plausible concern: The platelet-function study showed reduced platelet aggregation/adhesion with aged garlic extract, which could theoretically increase bleeding risk, especially when combined with anticoagulants/antiplatelet drugs. The studies reviewed here do not report bleeding events, so this remains a mechanistic caution rather than confirmed harm here.

  • Evidence gaps on adverse events: Several studies do not provide detailed adverse event reporting, dose standardization, or long-term safety outcomes, limiting conclusions about rare or delayed side effects.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report pharmacogenomic analyses (no genotype-stratified outcomes, no gene–supplement interaction testing, and no variant-specific safety signals). Therefore:

  • No evidence from these studies that garlic’s benefits or risks differ by genetic variation.

  • Practical implication: At present, based on these studies alone, garlic supplementation cannot be recommended or avoided on the basis of specific genotypes.

References

  1. The effect of garlic on the lowering of blood pressure in the patients with hypertension: an updated meta-analysis and trial sequential analysis
    Xiao Ma, Hongying Zhang, Jinhai Jia (2025)
  2. Aged garlic extract lowers blood pressure in patients with treated but uncontrolled hypertension: a randomised controlled trial
    Karin Ried, Oliver R Frank, Nigel P Stocks (2010)
  3. A double-blind crossover study in moderately hypercholesterolemic men that compared the effect of aged garlic extract and placebo administration on blood lipids
    M Steiner, A H Khan, D Holbert, R I Lin (1996)
  4. Garlic supplementation prevents oxidative DNA damage in essential hypertension
    Veena Dhawan, Sanjay Jain (2005)
  5. Aged garlic extract reduces blood pressure in hypertensives: a dose-response trial
    K Ried, O R Frank, N P Stocks (2013)
  6. Effects of Allium sativum (garlic) on systolic and diastolic blood pressure in patients with essential hypertension
    Rizwan Ashraf, Rafeeq Alam Khan, Imran Ashraf, Absar A Qureshi (2013)
  7. Changes in platelet function and susceptibility of lipoproteins to oxidation associated with administration of aged garlic extract
    M Steiner, R S Lin (1998)
  8. The role of garlic in hepatopulmonary syndrome: a randomized controlled trial
    Binay K De, Deep Dutta, Subrata K Pal, Subhabrata Gangopadhyay, Sumanta Das Baksi (2010)
  9. Gender- and age-related variations in blood viscosity in normal volunteers: a study of the effects of extract of Allium sativum and Ginkgo biloba
    J C F Galduróz, H K Antunes, R F Santos (2007)
  10. Inhibiting progression of coronary calcification using Aged Garlic Extract in patients receiving statin therapy: a preliminary study
    Matthew J Budoff, Junichiro Takasu, Ferdinand R Flores, Yutaka Niihara, Bin Lu (2004)
  11. Protective effect of chronic garlic intake on elastic properties of aorta in the elderly
    K Breithaupt-Grögler, M Ling, H Boudoulas, G G Belz (1997)
  12. Dietary supplementation with aged garlic extract inhibits ADP-induced platelet aggregation in humans
    K Rahman, D Billington (2000)
  13. Garlic at dietary doses does not impair platelet function
    Gisela Scharbert, Madeleine L Kalb, Monika Duris, Corinna Marschalek, Sibylle A Kozek-Langenecker (2007)
  14. Aged garlic extract, a modulator of cardiovascular risk factors: a dose-finding study on the effects of AGE on platelet functions
    M Steiner, W Li (2001)
  15. Effects of garlic consumption on physiological variables and performance during exercise in hypoxia
    David M Morris, Reid K Beloni, Hannah E Wheeler (2013)
  16. Lipid-lowering effects of time-released garlic powder tablets in double-blinded placebo-controlled randomized study
    Igor A Sobenin, Irina V Andrianova, Olga N Demidova, Tatiana Gorchakova, Alexander N Orekhov (2008)
  17. Effect of garlic and fish-oil supplementation on serum lipid and lipoprotein concentrations in hypercholesterolemic men
    A J Adler, B J Holub (1997)
  18. On the effect of garlic on plasma lipids and lipoproteins in mild hypercholesterolaemia
    L A Simons, S Balasubramaniam, M von Konigsmark, A Parfitt, J Simons (1995)
  19. Effect of garlic on serum lipids: an updated meta-analysis
    Karin Ried, Catherine Toben, Peter Fakler (2013)
  20. Effects of anethum graveolens and garlic on lipid profile in hyperlipidemic patients
    Javad Kojuri, Amir R Vosoughi, Majid Akrami (2007)


Related

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.

Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!